Early Stage Companies Announced

SEBIO 2019 > 2019 News > Early Stage Companies Announced

Presenting Companies

Early Stage Companies Announced

October 23, 2019 | 2019 News

Entrepreneurs representing the most promising early stage bioscience and medical technology companies in the region will solicit advice and seek investment during the annual life science convention sponsored by Southeast BIO, the regional nonprofit organization dedicated to fostering the growth of the southeast’s life sciences industry. The companies were picked by a selection committee of regional and national venture capitalists.

Early Stage companies will participate in forty-minute individual private advisory sessions behind closed doors with teams of investors, business advisors, service providers and successful entrepreneurs Wednesday, November 6.

Companies chosen for the Early Stage event are seeking their first rounds of institutional investment. The four best Early Stage companies will be selected to present to the full conference audience during the Early Stage Competition, with an overall winner announced at the lunch on Thursday, November 7.

“We are excited about this year’s group of Early Stage companies. They represent the Southeast region’s scientific diversity and entrepreneurial activity,” said Doug Gooding, Chair of the Early Stage Program.

Early Stage companies chosen to present at this year’s Forum are:

Achelios Therapeutics http://achelios.com/ (Chapel Hill, NC) clinical-stage specialty pharmaceutical company developing proprietary topical formulations of non-steroidal anti-inflammatory drug (NSAID) molecules to treat pain and inflammation

AMPEL BioSolutions, LLC http://ampelbiosolutions.com/ (Charlottesville, VA) technology company with CRO capabilities combining genomic technologies with advanced analytics to develop the Clinical Genomic Blood Test to match patients to the best therapy in clinical trials and clinical care

Ares Immunotherapy (Atlanta, GA) pre-clinical adoptive T cell therapy company based on technology discovered at the Medical University of South Carolina developing CD26+ CAR-T cells therapy specific for mesothelin for the treatment of mesothelioma and other solid tumors

Azure 8 (Atlanta, GA) medical device company developing the Sonix-A8TM, a Class II medical device to prevent and control surgical site and catheter-related bacterial infections

Cathaid https://www.cathaid.com/ (Augusta, GA) medical device company developing CathaidTM, a Class I medical device to better secure central venous catheters which allows real time detection of dangerous positional shifts and reduces infection

Dermasensor https://dermasensor.com/ (Miami, FL) medical device company developing a handheld wireless medical device for dermatologists that uses electron scattering microscopy combined with a proprietary algorithm to evaluate skin lesions for potential skin cancer

EDP Biotech, Inc. http://edpbiotech.com/ (Knoxville, TN) ISO-certified in vitro diagnostics company focused on the commercialization of ColoPlex™, a blood-based test aimed at early detection of colorectal cancer

Evren Technologies https://www.evrenvns.com/ (Newberry, FL) medical device company based on technology discovered at the University of Florida that is developing the PhoenixTM, a wearable device that provides transcutaneous vagal nerve stimulation for the treatment of post-traumatic stress disorder

IMMvention Therapeutix (Durham, NC) drug discovery start-up based on technology discovered at the University of North Carolina, Chapel Hill that is developing a pre-clinical pipeline of proprietary innate immunity specific therapies for autoimmune and inflammatory diseases

Inquisatex Epitherapeutics http://inquisatex.com/ (Charleston, SC) drug discovery start-up based on technology discovered at the Medical University of South Carolina developing a novel series of compounds for the treatment of Sickle Cell Disease.

KeViRx http://www.kevirx.com/ (Charlottesville, VA) pre-clinical oncology company based on technology discovered at the University of Virginia and the University of Pittsburgh developing KVR-053, an allosteric

PTP4A3 phosphatase small molecule inhibitor for ovarian, colorectal and breast cancers.

Oracle Health (Tampa, FL) medical device company developing a Digital Health enabled Insertable Cardiac Monitor (ICM) to follow Heart Failure progression and prevent Heart Failure hospitalization

Oxidien Pharmaceuticals https://www.oxidien.com/ (Gainesville, FL) clinical stage drug development company with proprietary enzyme assets to treat hyperoxaluria, a severe and debilitating condition causing renal damage, progressive chronic kidney disease, and end-stage renal failure

Park Surgical Innovations (Atlanta, GA) medical device company developing the Park Surgical Graft Delivery System, a class II medical device and method for delivering a prosthetic graft for laparoscopic ventral hernia repair

Plakous Therapeutics https://plakoustherapeutics.com/ (Winston-Salem, NC) pre-clinical regenerative medicine company developing Protego-PD™, an acellular placental derived platform product for the treatment of necrotizing enterocolitis (NEC) and osteoarthritis (OA)

Pyrefin, Inc. (Atlanta, GA) pre-clinical drug discovery company based on technology discovered at Emory University developing orally-active small molecule antagonists of the prostaglandin E2 (EP2) receptor for the treatment of pain and inflammation